Targeting PIK3C2A to improve treatment for triple-negative breast cancer
PIK3C2A is a vulnerable immunotherapeutic target in triple-negative breast cancer combination therapy
This study is looking at how a protein called PIK3C2A affects the immune system's ability to fight triple-negative breast cancer, with the goal of finding better treatments that help your body recognize and attack the cancer more effectively.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10997500 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of immunotherapy for patients with triple-negative breast cancer (TNBC) by targeting a specific protein called PIK3C2A. The study aims to improve tumor antigen presentation, which is crucial for the immune system to recognize and attack cancer cells. By understanding how PIK3C2A influences the immune response in TNBC, researchers hope to develop combination therapies that can lead to better patient outcomes. The approach involves genetic and molecular techniques to manipulate the expression of PIK3C2A in cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who may benefit from enhanced immunotherapy treatments.
Not a fit: Patients with non-triple-negative breast cancer or those who do not respond to immunotherapy may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Wang, Xiyu — Indiana University Indianapolis
- Study coordinator: Wang, Xiyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.